Loading...
•
Dec 31, 2022
Gilead Sciences Q4 2022 Earnings Report
Gilead Sciences' Q4 2022 financial results were announced, showcasing revenue growth driven by Oncology, HIV, and HCV, partially offset by lower Veklury sales.
Key Takeaways
Gilead Sciences announced its Q4 2022 financial results, with total revenue increasing by 2% to $7.4 billion. The growth was primarily driven by increased sales in Oncology, HIV, and HCV, which was partially offset by lower Veklury sales. Diluted EPS increased to $1.30, and non-GAAP diluted EPS increased to $1.67.
Total Q4 2022 revenue increased by 2% to $7.4 billion compared to Q4 2021.
Diluted Earnings Per Share (EPS) increased to $1.30 for Q4 2022, compared to $0.30 for the same period in 2021.
Non-GAAP diluted EPS increased to $1.67 for Q4 2022, compared to $0.69 for the same period in 2021.
HIV product sales increased 5% to $4.8 billion for Q4 2022 compared to the same period in 2021.
Gilead Sciences
Gilead Sciences
Gilead Sciences Revenue by Segment
Gilead Sciences Revenue by Geographic Location
Revenue by Segment
HIV Revenue
CapyFin.comRevenue by Geographic Location
U.S. Revenue
CapyFin.comEurope Revenue
CapyFin.comRest of World Revenue
CapyFin.com Forward Guidance
Gilead provided full-year 2023 guidance, projecting total product sales between $26.0 billion and $26.5 billion, and non-GAAP earnings per share between $6.60 and $7.00.
Positive Outlook
- Total product sales between $26.0 billion and $26.5 billion.
- Total product sales, excluding Veklury, between $24.0 billion and $24.5 billion.
- Earnings per share between $5.30 and $5.70.
- Non-GAAP earnings per share between $6.60 and $7.00.
- Veklury sales will be updated on a quarterly basis as necessary.
Challenges Ahead
- Total Veklury sales of approximately $2.0 billion are expected to be highly variable, depending on the frequency and severity of surges.
- Uncertainty around the duration and magnitude of the COVID-19 pandemic.
- Potential adverse revenue impacts from COVID-19.
- Financial guidance is subject to a number of risks and uncertainties.
- Gilead's ability to make progress on any of its long-term ambitions or strategic priorities laid out in its corporate strategy.